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Abstract
The natural disease course of chronic obstructive pulmonary disease (COPD) is often punctuated by exacerbations:
acute events of symptom worsening associated with significant morbidity and healthcare resource utilization; reduced
quality of life; and increased risk of hospitalization and death. The Global Initiative for Chronic Obstructive Lung Disease
(GOLD) recommend that patients at risk of exacerbations (GOLD Groups C and D) receive a long-acting muscarinic
antagonist (LAMA) or a long-acting β2-agonist (LABA)/LAMA combination, respectively, as preferred initial treatments.
The latter recommendation is based on recent trial evidence demonstrating the superior efficacy of a fixed-dose
LABA/LAMA over an inhaled corticosteroid (ICS)/LABA in exacerbation prevention. ICS in combination with a LABA is
also indicated for prevention of exacerbations, but the use of ICS is associated with an increased risk of adverse events
such as pneumonia, and offers limited benefits beyond those provided by LABA or LAMA monotherapy. In this review,
we examine evidence from a number of pivotal studies of LABAs and LAMAs, administered as monotherapy or as part
of dual or triple combination therapy, with a specific focus on their effect on exacerbations. We also discuss a new
proposed treatment paradigm for the management of COPD that takes into account this recent evidence and adopts
a more cautious approach to the use of ICS. In alignment with GOLD 2017, we suggest that ICS should be reserved for
patients with concomitant asthma or in whom exacerbations persist despite treatment with LABA/LAMA.
Keywords: Dual bronchodilation, ICS, LABA, LAMA, Treatment guidelines, Triple therapy
Background
The natural trajectory of chronic obstructive pulmonary
disease (COPD) is punctuated by exacerbations, defined
as an acute worsening of symptoms that results in
additional therapy [1, 2]. In many cases, exacerbations are
triggered by respiratory tract infections (predominantly
viral, but also bacterial) and environmental factors such as
air pollution, yet in approximately one third of cases, the
cause remains unknown [3].
COPD exacerbations have a marked negative effect on
both the patient and underlying disease processes, and can
result in hospitalization and readmission, an increased risk
of death [4] and a significant reduction in health status
[5, 6]. Exacerbations are also associated with long-term
decline in lung function and a high socioeconomic cost
[7–10]. Thus, optimizing the prevention and management
of COPD exacerbations is an important clinical issue.
A key step towards meeting this goal is to identify
patients at greatest risk of exacerbation. The ‘frequent
exacerbator’ phenotype (≥2 exacerbations/year) describes
patients who are particularly susceptible to exacerba-
tions, in contrast to infrequent exacerbators [11, 12].
The exacerbator phenotype, which remains relatively
stable over time [12], has a complex pathophysiology
and is prevalent across all disease severities, but is more
common in patients with worse lung function [12].
The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) provides treatment recommendations
for patients who are at high risk of exacerbation: a long-
acting muscarinic antagonist (LAMA) or a long-acting
β2-agonist (LABA)/LAMA combination are recom-
mended as primary choice treatment for these patients.
Although the GOLD strategy document was developed
with an international audience in mind, some countries
and regions (e.g. Spain, UK, South America, and
Canada) follow guidance outlined in their own recom-
mendations as well [13–16].
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Inhaled corticosteroids (ICS) are recommended for
patients at high risk of exacerbation with concomitant
asthma, or who experience further exacerbations follow-
ing initial bronchodilator treatment [2]. However, there is
widespread evidence of inappropriate use of ICS in
patients at low risk of exacerbation [17, 18]. Considering
the known risks associated with long-term ICS use, only
patients carefully considered as suitable candidates should
receive treatment with the appropriate ICS and associated
dose, such that treatment benefit will outweigh any
potential risk [19].
Strong evidence supports the favorable efficacy and
safety profile of dual bronchodilators. Compared with
bronchodilator monotherapy and ICS/LABA, LABA/
LAMAs improve lung function [20–29] and reduce
exacerbation risk [23, 24, 28, 29]. The safety profile of
LABA/LAMA combinations is generally similar to that
of placebo or individual monocomponents [22, 30–33].
However, LABA/LAMA use is still relatively limited
and further experience with these agents is needed [34].
In this review, we will examine the efficacy of various
COPD treatments in terms of exacerbation prevention,
with particular focus on bronchodilators, and discuss a new
proposed treatment paradigm for reducing exacerbation
risk in patients with COPD.
Efficacy Of Bronchodilators In Prevention Of
Exacerbations
Non-pharmacological intervention
Smoking cessation is the most effective initial strategy
for reducing COPD disease progression, particularly
exacerbation risk [2, 35]. Smoking cessation significantly
reduces the progressive decline in lung function [36],
and substantially lowers the risk of mortality [37], how-
ever a significant number of COPD patients continue
to smoke [38]. Although smoking cessation results in a
reduced rate of decline in lung function, disease pro-
gression may persist [39].
Influenza vaccination can reduce serious illness and
death in patients with COPD [40–43].
Furthermore, a significant reduction in exacerbation
rate has also been observed with vaccination versus
placebo [40]. Findings from a population-based study
suggested that COPD patients, especially the elderly, had
a decreased risk of ischemic heart disease when receiving
the influenza vaccine over many years [44].
Pulmonary rehabilitation (PR) reduces hyperinflation by
promoting lung deflation and better lung ventilation,
which is linked to an improved health status and exercise
capacity [45]. PR also provides benefits that extend
beyond the initial training period, such as: improved
survival; improved recovery following hospitalization for
exacerbation; reduced perceived intensity of breathless-
ness; and reduced anxiety and depression [2, 46, 47]. PR
programs can significantly reduce the frequency of
exacerbations and hospitalization, and the proportion
of patients classified as ‘frequent exacerbator’ [48].
Non-pharmacological interventions, such as surgical
modes or bronchoscopic modes of lung volume reduc-
tion, are also associated with a reduction of exacerba-
tion; however, these interventions are limited to a small
number of patients [49].
Encouraging patients to increase their levels of daily
activity is also recommended, due to the general benefi-
cial effects of physical exercise [2] and the reported links
between lower levels of physical activity in patients with
COPD and an increased risk of hospitalization [50, 51]
and readmission [52].
Pharmacological interventions
It must be recognized that many studies presented here
were not designed to test for the relative efficacy of treat-
ments in exacerbation prevention, making it difficult to
draw conclusions on their effects in at-risk populations.
However, the following studies were powered to test for
differences in exacerbation rate, and recruited patients at
high risk of exacerbation, thus, enriching study popula-
tions: POET (1 year) [53]; SPARK (64 weeks) [24]; FLAME
(52 weeks) [29]; and INSPIRE (2 years) [54].
Single bronchodilation versus placebo in the prevention
of exacerbations
The two main classes of bronchodilators are β2-agonists
and muscarinic receptor antagonists. Both classes of
bronchodilators improve patients’ ability to breathe by
relaxing airway smooth muscle, thereby reducing respira-
tory muscle activity and dynamic hyperinflation, and
improving ventilatory mechanics [55–57]. Exacerbations
are mainly triggered by infections associated with small
airway inflammation [3], however environmental condi-
tions, such as pollution, may also initiate or amplify these
events [2]. The mechanisms by which bronchodilators
prevent exacerbations are unclear, yet are thought to
include decreased hyperinflation and mechanical stress,
decreased mucus production and enhanced mucociliary
clearance, the improvement of symptom severity and fluc-
tuation, and potential anti-inflammatory properties [58].
Compared with placebo, the use of tiotropium 18 μg once
daily (q.d.) was associated with sustained reductions in
lung hyperinflation and inspiratory capacity both at rest
and during exercise, contributing to improvements in
exertional dyspnea and increased exercise endurance in
patients with COPD [57]. Treatment with formoterol
12 μg twice daily (b.i.d.) significantly enhanced mucus
clearance compared with tiotropium 18 μg q.d. in patients
with mild-to-moderate COPD [59]. AUGMENT demon-
strated that treatment with both formoterol 12 μg b.i.d.
and aclidinium 400 μg b.i.d. significantly improved
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dyspnea and health status compared with placebo in
patients with moderate-to-severe COPD [60]. Compared
with formoterol 12 μg b.i.d., tiotropium 18 μg q.d.
demonstrated a superior anti-inflammatory activity pro-
file, significantly reducing the production of superoxide
and pro-inflammatory mediators in COPD patients [61].
Traditionally, much of the evidence for the efficacy of
LAMAs in exacerbation prevention has come from stu-
dies with tiotropium. More recently, there have been
similar findings with glycopyrronium, aclidinium and
umeclidinium, as well as the LABAs salmeterol and
indacaterol. Table 1 summarizes the findings from major
trials of these agents with regards to exacerbation preven-
tion, although it should be noted that exacerbations were
studied as a secondary endpoint in the majority of cases.
Most of the 11 studies comparing tiotropium (5 or
10 μg q.d., via the soft-mist inhaler, or 18 μg q.d. via dry-
powder inhaler) with placebo reported significant benefi-
cial effects on various exacerbation-related outcomes. In
nine studies, the number of exacerbation events per
patient per year was significantly lower with tiotropium
than placebo [62–70]. Eight studies reported significant
delays in the time to first exacerbation with tiotropium
versus placebo [62–69], and in six studies the proportion
of patients experiencing one or more exacerbations, and
the number of exacerbation days per year, were significantly
lower with tiotropium than with placebo [62, 64–70]. Only
three studies reported significantly lower hospitaliza-
tions due to exacerbation (rates, events or proportions
of patients) with tiotropium [62, 64, 70]. Glycopyrro-
nium (50 μg q.d.) [71, 72], aclidinium (200 or 400 μg
b.i.d. [73, 74], umeclidinium (62.5 μg and 125 μg q.d.)
[22, 75], salmeterol (50 μg b.i.d.) [76] and indacaterol
(doses ranging from 150–600 μg q.d.) [77–79] have dem-
onstrated similar beneficial effects compared with placebo.
In two pivotal studies, GLOW1 (26 weeks) and GLOW2
(1 year), glycopyrronium (50 μg q.d.) significantly pro-
longed time to first moderate-to-severe exacerbation ver-
sus placebo [71, 72]. In GLOW1, glycopyrronium also
significantly reduced the risk of severe COPD exacerba-
tions leading to hospitalization and the proportion of hos-
pitalizations due to COPD exacerbations [71]. In GLOW2,
glycopyrronium significantly reduced the rate of
moderate-to-severe exacerbations and the number of
exacerbations requiring treatment with systemic cortico-
steroids or antibiotics, versus placebo [72].
In ACCORD (12 weeks) and ATTAIN (24 weeks),
aclidinium (200 or 400 μg b.i.d.) significantly reduced
the rate of exacerbations of any severity and numeric-
ally reduced rates of moderate or severe exacerbations
per patient per year compared with placebo [73, 74].
Two 24-week studies examining the efficacy of umecli-
dinium demonstrated significant reductions in the risk
of exacerbations versus placebo [22, 75].
Comparison of the efficacy of single bronchodilators in
the prevention of exacerbations
Only a few head-to-head studies have examined the rela-
tive effects of different bronchodilators on exacerbation
outcomes (Table 2).
The first study to specifically test the efficacy of a LABA
versus a LAMA in exacerbation prevention was POET, a
randomized, double-blind, double-dummy, parallel-group
trial in patients with moderate-to-very-severe COPD and
a history of exacerbations. Compared with salmeterol
(50 μg b.i.d.), tiotropium (18 μg q.d.) delayed the time to
first exacerbation and significantly reduced the risk of
exacerbation (187 days versus 145, respectively; hazard
ratio [HR] 0.83; p < 0.001). Tiotropium also significantly
prolonged the time to first severe exacerbation (HR 0.72;
p < 0.001) and reduced the annual rates of severe, and
moderate or severe exacerbations versus salmeterol (rate
ratios [RR], 0.73 [p < 0.001] and 0.89 [p = 0.002], respect-
ively) [53]. Similar findings were reported in INVIGOR-
ATE, where tiotropium (18 μg q.d.) significantly reduced
annualized exacerbation rate versus indacaterol (150 μg
q.d.) (0.73 versus 0.90; RR 1.24; p < 0.0001) [80].
To date, no direct head-to-head, LAMA versus LAMA
studies have been performed. In GLOW2, open-label
tiotropium (18 μg q.d.) was included as a reference arm;
however, the study was not designed nor powered to test
for differences between the two active treatments.
Compared with placebo, exacerbation risk was reduced
with glycopyrronium (HR 0.66; p = 0.001) and with
tiotropium (HR 0.61; p = 0.001), although no formal
comparisons between the two treatments were made
[72]. In SPARK, which studied the efficacy of indaca-
terol/glycopyrronium (IND/GLY 110/50 μg q.d.) com-
pared with glycopyrronium (50 μg q.d.) and tiotropium
(18 μg q.d.) in patients with severe-to-very severe COPD
and an exacerbation history, the rate of moderate or se-
vere exacerbations was similar between glycopyrronium
and tiotropium monotherapies (HR 1.03; p = 0.68) [24].
Dual bronchodilation versus placebo in the prevention of
exacerbations
The mechanisms underlying interactions between LABAs
and LAMAs have not been fully elucidated. However, β2-
agonists can amplify muscarinic antagonist-mediated
smooth muscle relaxation by modulating cholinergic
neurotransmission and decreasing acetylcholine release,
and muscarinic antagonists can augment β2-agonist-medi-
ated bronchodilation by reducing the bronchoconstrictor
effects of acetylcholine [81]. The complimentary mech-
anisms of action of LABAs and LAMAs elicit additive
effects on lung function, and provide a rationale for
combining the two agents to optimize bronchodilation.
Mechanisms that most likely involve reduced airway
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resistance, improved inspiratory capacity and reduced
hyperinflation may confer benefits in terms of exacer-
bations [58].
Numerous dual bronchodilators have been developed
with this aim in mind. They include once-daily IND/
GLY, umeclidinium/vilanterol (UMEC/VI) and tiotro-
pium/olodaterol (TIO/OLO), and twice-daily aclidi-
nium/formoterol (A/F) and glycopyrrolate/formoterol
fumarate (GLY/F). In the USA, IND/GLY has been
developed for twice-daily use [82]. Table 1 summarizes
data from studies comparing the effects of dual broncho-
dilators on exacerbations with placebo.
Exacerbation risk was significantly reduced relative to
placebo in UMEC/VI (62.5/25 and 125/25 μg) studies
[22, 75] whereas the effects of A/F were less consistent
across different doses (400/12 and 400/6 μg) and exacer-
bation assessments [23, 83]. In a prespecified analysis of
pooled data from ACLIFORM and AUGMENT, the
higher dose of A/F significantly reduced the rate of mod-
erate or severe exacerbations compared with placebo,
whether defined according to EXAcerbation of Chronic
Pulmonary Disease Tool (EXACT) criteria (RR 0.78;
p < 0.01) [84] or healthcare resource utilization (HRU;
RR 0.71; p < 0.05) [83]. The higher-dose combination
of A/F also prolonged time to first exacerbation of
any severity defined according to HRU (HR 0.72; p < 0.05)
or EXACT (HR 0.79; p < 0.05) versus placebo ([83]. There
are currently no published data comparing IND/GLY or
TIO/OLO with placebo [23, 83].
Dual versus single bronchodilation in the prevention of
exacerbations
As shown in Table 2, LABA/LAMAs can improve
exacerbation outcomes compared with monotherapy,
although not all studies were designed for this objective,
and the results are variable. In SPARK, an exacerbation
study, the annualized rate of moderate or severe exacer-
bations was significantly lower with IND/GLY versus
glycopyrronium (primary endpoint, RR 0.88; p = 0.038),
and rates of all exacerbations (mild, moderate or severe)
were significantly lower with IND/GLY versus either
glycopyrronium (RR 0.85; p = 0.0012) or tiotropium (RR
0.86; p = 0.0017) [24].
By contrast, in a 24-week study not designed for
studying exacerbation prevention, UMEC/VI (125/25 μg
q.d.) conferred no significant benefit for exacerbation
risk compared with individual monotherapies or with
tiotropium (18 μg q.d.) in patients with moderate-to-
very severe COPD [85]. The results of the ongoing 52-
week DYNAGITO trial (NCT02296138), comparing the
annualized rate of moderate-to-severe COPD exacerba-
tions (primary endpoint) with TIO/OLO (5/5 μg q.d.)
versus tiotropium (5 μg q.d.) in patients with severe-to-
very severe COPD, will therefore be of interest [86].
Single bronchodilation versus ICS/LABA combinations in
the prevention of exacerbations
Of the six ICS/LABA versus bronchodilator monother-
apy studies, only two demonstrated significant benefits
on exacerbations (Table 3) [87, 88]. It should be noted
that these studies were not all designed to compare the
effects of an ICS/LABA with single bronchodilation (but
with placebo), and exacerbation endpoints were often
secondary or exploratory.
One of the most robust studies was TORCH (3 years),
which studied deaths (any cause) as the primary outcome,
as well as exacerbation frequency between treatments. In
TORCH, salmeterol/fluticasone propionate combination
(SFC 50/500 μg b.i.d.) significantly reduced the annual rate
of moderate or severe exacerbations compared with
salmeterol (50 μg b.i.d.; RR 0.88; p = 0.002) [87].
In a pooled analysis of two 1-year trials, in which the
primary endpoint was the yearly rate of moderate and
severe exacerbations, fluticasone furoate/vilanterol (FF/
VI; 50/25 μg, 100/25 μg and 200/25 μg q.d.) significantly
reduced the rate of moderate or severe exacerbations
compared with vilanterol (25 μg q.d.; p < 0.05 for all
three doses) [88]. FF/VI (100/25 μg and 200/25 μg q.d.)
also significantly prolonged time to first moderate or
severe exacerbation versus vilanterol monotherapy (HR
0.8; p = 0.0365 and HR 0.7; p = 0.0001, respectively), and
significantly reduced the number of exacerbations re-
quiring systemic corticosteroids (p < 0.05 and p = 0.0009,
respectively) [88].
In a post-factorial analysis of SUMMIT, FF/VI (100/25 μg
q.d.) significantly reduced the rate of moderate or severe
exacerbations versus fluticasone (100 μg q.d.; p < 0.001) and
versus vilanterol (25 μg q.d.; p < 0.001) [89].
Only INSPIRE has compared an ICS/LABA with LAMA
monotherapy in exacerbation prevention [54]. No signifi-
cant difference was observed between SFC (50/500 μg
b.i.d.) and tiotropium (18 μg q.d.) in HRU exacerbation
rate (1.28 and 1.32, respectively) in this study [54].
Dual bronchodilation versus ICS/LABA combinations in
the prevention of exacerbations
Exacerbation data are available from a number of studies
comparing a LABA/LAMA with an ICS/LABA (Table 3).
In a post-hoc analysis of ILLUMINATE (26 weeks),
IND/GLY (110/50 μg q.d.) significantly reduced the time
to first exacerbation (HR 0.65; p = 0.03) versus SFC
(50/500 μg b.i.d.), in patients with moderate–to-severe
COPD and no exacerbations in the previous year
[90]. Likewise, in LANTERN (26 weeks), IND/GLY
(110/50 μg q.d.) significantly reduced the rate of
moderate or severe exacerbations (RR 0.69; p = 0.048)
compared with SFC (50/500 μg b.i.d.), in patients
with moderate-to-severe COPD and ≤1 exacerbations
in the previous year [28]. In a post-hoc analysis of
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pooled data from LANTERN and ILLUMINATE, the
annualized rate of moderate or severe exacerbations
was significantly lower with IND/GLY versus SFC, in
both the whole population (p = 0.02) and in subgroups
of patients classified as either GOLD Group B (p =
0.16) or GOLD Group D (p = 0.05; patients were clas-
sified according to GOLD 2009 and 2010 for ILLU-
MINATE and LANTERN, respectively). Furthermore,
IND/GLY delayed the time to first moderate or severe
exacerbation compared with SFC in the overall popu-
lation and in GOLD Group B and GOLD Group D
subgroups [91].
The most recent study comparing a LABA/LAMA
with an ICS/LABA was FLAME, which specifically stud-
ied the differences in exacerbations between IND/GLY
(110/50 μg q.d) and SFC (50/500 μg b.i.d.) as the pri-
mary outcome, and included an enriched patient popula-
tion at high risk of exacerbation (≥1 exacerbation in the
previous year) [29]. Compared with SFC, IND/GLY sig-
nificantly reduced the rate of all COPD exacerbations
(RR 0.89; p = 0.003), and the rate of moderate or severe
exacerbations (RR 0.83; p < 0.001). Additionally, IND/
GLY significantly prolonged the time to first exacerba-
tion (HR 0.84; p < 0.001). The time to first moderate or
severe exacerbation (HR 0.78; p < 0.001), and time to the
first severe exacerbation (HR 0.81; p = 0.046) were also
significantly prolonged with IND/GLY versus SFC.
Treatment benefit or time to first exacerbation was
detected as early as 4 weeks. Compared with SFC, IND/
GLY numerically, but not significantly, reduced the rate
of exacerbations in patients with a history of ≥2 exacer-
bations in the previous year, (19% of the patient popula-
tion). However, it is worth noting that this was a
subgroup analysis and FLAME was not powered to
detect treatment differences in subgroups [29].
In a 24-week trial comparing A/F (400/12 μg b.i.d.)
with SFC (50/500 μg b.i.d), a similar proportion of
patients experienced at least one exacerbation in the A/F
and SFC groups, regardless of exacerbation definition
(HRU or EXACT criteria) [27]. However, the study was not
designed to test exacerbations.
To date, there have been no long-term studies
examining the effects of UMEC/VI or TIO/OLO on exac-
erbations in at-risk patients. Two 12-week studies com-
paring the efficacy of UMEC/VI (62/25 μg q.d.) and SFC
(50/250 μg b.i.d.) captured exacerbations as safety data
and did not perform statistical testing [26, 88]. Likewise,
in ENERGITO (a 12-week, randomized, double-blind,
four-treatment, crossover study comparing the efficacy of
TIO/OLO [5/5 μg and 5/2.5 μg q.d.] with SFC [50/500 μg
and 50/250 μg b.i.d.]), exacerbations were captured as
safety data (reported as an adverse event of ‘COPD
worsening’) [92]. Further long-term studies comparing
UMEC/VI and TIO/OLO are required.
Triple therapy in the prevention of exacerbations
Evidence for the efficacy of triple therapy (ICS/LABA/
LAMA) in exacerbation prevention is currently limited.
Nevertheless, in TRILOGY (1 year), the adjusted annual
rate of moderate-to-severe exacerbations was signifi-
cantly reduced following step-up to triple therapy
(beclomethasone dipropionate/formoterol fumarate/gly-
copyrronium bromide [BDP/FF/GB] 100/6/12.5 μg two
actuations b.i.d.) compared with continuing on BDP/FF
100/6 μg two actuations b.i.d. (0.41 versus 0.53, respect-
ively; RR 0.77; p = 0.005) [93].
Similarly, TRINITY (1 year) compared the fixed-dose
combination [FDC] of BDP/FF/GB (100/6/12.5 μg b.i.d.)
with a free combination of the same agents and LAMA
monotherapy (tiotropium 18 μg q.d.) in patients with
severe–to-very severe COPD. Compared with TIO,
BDP/FF/GB FDC significantly reduced the rate of
moderate/severe exacerbations (0.46 versus 0.57, respect-
ively; RR 0.80; p = 0.0025). BDP/FF/GB and BDP/FF + TIO
showed a similar effect on moderate/severe exacerbations
(RR 1.01) [94]. Findings are eagerly anticipated from the
ongoing InforMing the PAthway of COPD Treatment
(IMPACT) study, comparing the rate of moderate and se-
vere exacerbations between FF/UMEC/VI and FF/VI or
UMEC/VI over 52-weeks in symptomatic COPD patients
with an exacerbation in the previous 12 months [95].
Other Pharmacological Treatments In The
Prevention Of Exacerbations
Mucolytics in the prevention of exacerbations
Mucolytics are oral medicines designed to reduce
mucus and sputum viscosity, thereby making it easier
for patients to cough up mucus and clear it from the
airways [96]. The current GOLD recommendations
recognize that regular use of mucolytics may be benefi-
cial in patients not receiving ICS, to reduce exacerba-
tions and improve health status [2].
The antioxidant N-acetylcysteine (NAC; 600 mg/day),
is recommended by the American College of Chest
Physicians and Canadian Thoracic Society for patients
with moderate-to-severe COPD and a history of two or
more exacerbations in the previous 2 years [97]. How-
ever, NAC 600 mg/day is currently not approved for
use in the USA. In a 6-month study, the number of ex-
acerbations was reduced by 41% with standard therapy
plus NAC versus standard therapy alone, and fewer pa-
tients experienced at least one exacerbation (46 versus
63 patients, respectively) [98]. In PANTHEON (1 year),
NAC (600 mg/b.i.d.) significantly reduced the annual
rate of exacerbations versus placebo (1.16 versus 1.49
exacerbations per patient-year; p = 0.0011) [99]. By con-
trast, in BRONCUS (3 year), a randomized, placebo-
controlled study, there was no difference between NAC
(600 mg/day) and placebo in the number of
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exacerbations per year (a primary outcome, [1.25 versus
1.29; p = 0.85]), although sub-group analyses suggested
that NAC might have reduced exacerbation rate in pa-
tients not receiving ICS treatment [100]. In a 2015
meta-analysis of 13 studies (N = 4155), NAC
significantly reduced the relative risk of exacerbations
in patients with COPD and/or chronic bronchitis. The
authors concluded that a dose of 600 mg b.i.d. should
be used in patients who have both chronic bronchitis
and COPD, whereas the standard 600 mg/day dose
should suffice for patients who have chronic bronchitis
alone [101]. Accordingly, one study showed that NAC
(600 mg b.i.d.) was more effective than placebo in redu-
cing exacerbation risk and prolonging time to first
exacerbation in high-risk patients (GOLD Groups C
and D, according to the 2011 GOLD recommenda-
tions), but not low-risk patients [102].
Two studies have examined the effects of erdosteine
on exacerbations. EQUALIFE, an 8-month, randomized,
double-blind trial, demonstrated that patients taking
erdosteine (300 mg b.i.d.) had significantly fewer exacer-
bations and spent fewer days in hospital than those on
placebo [103]. More recently, Moretti et al demonstrated
that 10-day treatment with erdosteine (900 mg/day) was
associated with a 39% lower risk of exacerbations in the
2 months post-discharge and a significant delay in time
to first exacerbation at post-discharge days 30 (p =
0.009) and 60 (p = 0.075) compared with placebo, in pa-
tients hospitalized following acute exacerbation [104]. In
a 6-month, randomized trial, a significantly higher pro-
portion of patients experienced no exacerbations when
treated with continuous carbocysteine lysine salt mono-
hydrate (SCMC-Lys; 2.7 g q.d.) compared with placebo
(p < 0.001) [105]. Similarly, in PEACE (1 year), the annu-
alized rate of exacerbations was significantly lower with
carbocysteine (1500 mg/day) than with placebo, repre-
senting a 25% reduction in risk (p = 0.004) [106].
Phosphodiesterase-4 inhibitors in the prevention of
exacerbations
Phosphodiesterase-4 (PDE-4) inhibitors can inactivate
immune and inflammatory cells by blocking the metabol-
ism of cyclic adenosine monophosphate (cAMP) [107].
GOLD recommends addition of the selective, long-acting
PDE-4 inhibitor roflumilast to a ICS/LABA/LAMA in
GOLD Group D patients who continue to experience
exacerbations despite triple therapy, particularly patients
with a forced expiratory volume in one second (FEV1)
<50% predicted, chronic bronchitis, and ≥1 hospitalization
for an exacerbation in the previous year [2].
A meta-analysis of 13 studies suggested that roflumi-
last (500 μg q.d.) was more effective than placebo in
reducing the rate of acute exacerbations (p < 0.001)
[107]. In REACT, roflumilast (500 μg q.d.) reduced the
rate of moderate-to-severe exacerbations by 13.2%
versus placebo in patients with severe COPD, chronic
bronchitis and at risk of frequent and severe exacerba-
tions, and receiving ICS/LABA treatment with or with-
out tiotropium (Poisson regression analysis, p = 0.0529)
[108]. In a post-hoc analysis of RE(2)SPOND (52 weeks),
roflumilast (500 μg q.d.) significantly reduced the rate of
moderate or severe exacerbations versus placebo in
patients with severe-to-very severe COPD and chronic
bronchitis, a history of >3 exacerbations and/or ≥1
hospitalizations in the prior year [109]. Roflumilast is in-
dicated as a maintenance treatment (added on to bron-
chodilator therapy) in adults with severe COPD
associated with chronic bronchitis, and a history of
frequent exacerbations [110].
Macrolides in the prevention of exacerbations
Macrolides are antibiotics with antimicrobial, anti-
inflammatory, and immunomodulating effects. GOLD
2017 recommends the addition of a macrolide to an
ICS/LABA/LAMA regimen in GOLD Group D patients
who are former smokers and continue to suffer exacer-
bations despite triple therapy [2]. In COPD, the best
studied macrolide is azithromycin. COLUMBUS (1 year)
demonstrated that exacerbation rate was significantly
reduced with azithromycin (500 mg three times/week),
compared with placebo (odds ratio = 0.58, p = 0.001), in
patients with COPD who had received treatment for ≥3
exacerbations in the previous year despite optimal inhal-
ation therapy [111]. Similar findings were reported in a
1-year, randomized, controlled trial in patients with
COPD at risk for exacerbations, where azithromycin
(250 mg q.d.) significantly delayed median time to first
exacerbation (266 versus 174 days; p < 0.001), and
significantly reduced the frequency of exacerbations
(1.48 versus 1.83; p = 0.01) versus placebo [112]. Similar
results have been reported in other, smaller studies
comparing erythromycin and placebo [113, 114].
Appropriate use of ICS
Much evidence supports the use of ICS in patients with
persistent asthma, yet the role of ICS in preventing exac-
erbations of COPD is less clear [19, 115]. Various meth-
odological issues in trial design and/or statistical analysis
affect results and make subsequent study interpretation
difficult [116].
However, data are emerging to suggest that raised
blood or sputum eosinophil levels could predict a posi-
tive response (i.e. a reduction in exacerbations) to ICS/
LABA versus LABA monotherapy, or predict any dele-
terious effects ICS withdrawal may have [117–121].
The potential association between this ‘eosinophilic
phenotype’ and a positive response to ICS requires fur-
ther investigation, as the effect has not been consistent
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across studies within the same analysis [118], and may
only be present in patients with a history of ≥2 exacerba-
tions in addition to raised eosinophil levels [121]. Pro-
spective analysis of FLAME (which excluded patients
with a previous diagnosis of asthma and/or a blood eo-
sinophil count >600/mm3), demonstrated that IND/GLY
was superior to SFC in reducing the rate of moderate-
to-severe exacerbations, regardless of baseline eosinophil
levels [29]. Thus, further studies are needed before any
recommendations can be made regarding the potential
use of ICS in specific sub-populations.
Proposed Treatment Paradigm
Figure 1 shows a proposed treatment paradigm for ex-
acerbation prevention based on the evidence presented
and centered on optimal use of bronchodilation, which
has previously been published [122–124].
Conclusions
Not only do COPD exacerbations negatively impact the
underlying disease course, but they also have a detri-
mental effect on patients’ lives, resulting in lung function
decline, increased risk of mortality and poor health sta-
tus. While there has been a tendency to recommend the
use of ICS for patients at high risk of exacerbations, ICS
are associated with a myriad of side effects such as
pneumonia. However, (and as recognized in the updated
GOLD strategy document) evidence is emerging that
suggests there may be more appropriate treatment strat-
egies for many at risk patients, including a LABA/
LAMA combination.
The proposed treatment paradigm for exacerbation
prevention is centered on optimizing bronchodilation as
an initial pharmacological step, first with a LAMA, and
subsequently with a dual LABA/LAMA should symptoms
Fig. 1 A proposed treatment algorithm for the treatment of chronic obstructive pulmonary disease (COPD). FEV1, forced expiratory volume in 1 s;
GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LAMA, long-acting
muscarinic antagonist; PDE-4, phosphodiesterase-4 [134]
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worsen or exacerbation occur. Only if patients continue to
suffer exacerbations do we suggest the addition of an ICS
or a PDE-4 inhibitor, depending on patient profile/pheno-
type. It is possible that a subgroup of patients with COPD
who have raised blood or sputum eosinophils may respond
better than others to ICS, although current data are still
preliminary and somewhat contradictory. Future studies
are warranted to better define the groups who may benefit
from ICS, and to identify the mechanisms by which bron-
chodilation reduces exacerbations.
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